LGALS3 signaling and macrophage ferroptosis in steatohepatitis

Abstract

Finding effective treatments for metabolic dysfunction-associated steatohepatitis (MASH) remains a primary challenge in hepatology. Hepatic fibrosis rarely depends on a single biological trigger. It develops through a complex overlap of metabolic stress, local immune activation, and chronic tissue injury. Recent laboratory evidence shows that Qiweizhigan granules reduce steatohepatitis severity, lowering both liver iron deposition and oxidative stress. The investigators linked these structural improvements to an LGALS3-TRAF6-GPX4 signaling cascade inside macrophages. By introducing a chemical TRAF6 inhibitor, the research team halted LGALS3-driven iron accumulation and restored GPX4 function, adding weight to this proposed mechanism. Although further studies must confirm absolute causality, this pathway provides a highly useful template for translation. The data suggest that repairing MASH requires researchers to address inflammatory signaling and ferroptosis simultaneously. For those developing botanical therapies, this specific cellular axis offers clear biological nodes. Developers can use these markers to establish potency assays, track lot-to-lot consistency, and define the exact clinical role of multi-herb formulas.

Key Words: Metabolic dysfunction-associated steatohepatitis; LGALS3; Ferroptosis; GPX4; Macrophage; Traditional Chinese medicine; Botanical drug development; Fibrosis

Core Tip: Macrophage-linked ferroptosis has emerged as a plausible injury-amplifying layer in steatohepatitis. A recent study of Qiweizhigan granule proposes an LGALS3-TRAF6-GPX4 framework connecting inflammatory activation to ferroptotic vulnerability. Its main value lies in generating a testable translational model rather than a settled mechanism. Future progress will depend on cell-specific causality, human-relevant validation, mechanism-linked potency assays, and clinically deployable biomarker strategies.

INTRODUCTION

In metabolic dysfunction-associated steatohepatitis (MASH), long-term outcome is largely determined by fibrosis stage, but sustained fibrosis regression is still difficult to achieve in routine care. Large-scale prognostic evidence links more advanced fibrosis to higher risks of liver-related events and mortality, which is why therapies that only improve steatosis or inflammatory activity for a short period are unlikely to be enough[1]. Within this network, hepatic macrophages, including resident Kupffer cells and recruited monocyte-derived cells, integrate danger signals and shape fibrotic niches, making macrophage programs plausible targets for disease modification[2].

Regulated cell death is a second layer worth considering. Mechanistic studies of steatohepatitis increasingly consider ferroptosis because it links oxidative stress and iron imbalance with inflammatory injury[3]. At the same time, approval-era data have altered the therapeutic landscape: In phase 3 testing, resmetirom produced histological benefit in noncirrhotic MASH with fibrosis, but variable treatment responses and the biologic complexity of the disease suggest that not all patients will be served by the same mechanism of action[4]. Whether ferroptosis operates mainly in hepatocytes, within macrophage-amplified inflammation, or across several interacting cell populations remains unsettled[3,4].

The featured report shows that the multi-herb formula Qiweizhigan (QWZG) improves experimental MASH and advances a macrophage-centered LGALS3-TRAF6-GPX4 cascade that connects inflammatory signaling to ferroptotic vulnerability[5]. A remaining question is whether macrophage-associated ferroptosis offers a useful mechanistic basis for evaluating multi-component botanical therapies in MASH. This opinion review discusses that study together with the relevant literature on liver macrophages, LGALS3-3 signaling, ferroptosis, and clinical development. It separates what is already supported from what remains inferential and indicates which questions need direct follow-up.

CURRENT PROGRESS IN THE FIELD AND WHAT THE FEATURED STUDY ADDS

Current evidence in MASH indicates that disease-associated hepatic macrophages are active participants in steatohepatitis progression and inflammasome-related injury, not passive bystanders[6]. Experimental studies in liver disease also continue to implicate galectin-3 in immune-fibrotic signaling, which keeps attention on macrophage-centered mechanisms[7,8].

The featured work tested the traditional multi-herb formula QWZG granules in an experimental MASH model and linked macrophage inflammatory amplification to ferroptotic vulnerability. In the choline-deficient, L-amino acid-defined, high-fat diet (CDAHFD) model, a standard platform for rapidly inducing steatohepatitis with progressive fibrosis, QWZG improved major disease readouts, including histological injury and fibrosis-related indices, while lowering oxidative stress and hepatic iron overload[5,9].

Transcriptomic profiling followed by cell-focused experiments identified LGALS3 as a Kupffer cell-enriched node responsive to QWZG. In macrophages, inflammatory stimulation increased LGALS3; enforced LGALS3 expression intensified inflammatory outputs and coincided with GPX4 reduction, the principal anti-ferroptotic defense, together with higher iron/Lipid peroxidation indices. In contrast, LGALS3 knockdown lowered iron accumulation, shifted ferroptosis-associated signals in the opposite direction, and allowed QWZG treatment to partly restore GPX4-related defenses under the same conditions[5].

One mechanistic point is the placement of TRAF6 between LGALS3-linked inflammatory signaling and GPX4 loss. Blocking TRAF6 decreased LGALS3-linked iron accumulation and enhanced GPX4-related metrics, which supports the proposed LGALS3-TRAF6-GPX4 sequence[5]. This interpretation is biologically plausible because TRAF6 is a well-established signal transducer in innate immune pathways that contribute to inflammasome priming and may therefore connect macrophage activation programs with downstream tissue injury cascades[10].

Overall, the current investigation functions better as a preliminary mechanistic proposal rather than a final conclusive proof. The data are compatible with the possibility that QWZG mitigates MASH by attenuating an LGALS3-centered inflammatory program and reducing ferroptotic vulnerability through TRAF6-associated regulation of GPX4. That model can now be tested in follow-up work using target-engagement and potency readouts[5].

A MACROPHAGE-CENTERED AXIS: LGALS3-TRAF6-GPX4 AND FERROPTOTIC VULNERABILITY

The question is whether this signaling chain fits current understanding of MASH pathogenesis. A macrophage-centered axis is appealing because hepatic macrophages sit at the interface of metabolic danger signals, innate immune amplification, and the fibrogenic microenvironment, given their ability to alter both parenchymal injury and stromal remodeling[2]. Recent experimental and human studies also suggest that macrophage heterogeneity and Kupffer cell fate are dynamically remodeled across steatotic liver disease and that macrophage-linked ferroptotic programs may themselves shape progression[6,11-14]. In that setting, a pathway affecting inflammatory tone through TRAF6-linked innate signaling and oxidative or iron-stress handling through GPX4-related ferroptosis defense offers a plausible explanation for how one intervention might influence several disease layers at once.

Kupffer cells as integrators of inflammatory and oxidative/iron signals

LGALS3, the proposed upstream node, already has substantial support in liver injury and fibrosis biology and is also relevant to recent human steatotic liver disease data. LGALS3 is induced in human fibrotic liver disease and regulates myofibroblast activation and collagen production in experimental fibrosis, indicating its role extends beyond a mere passive inflammatory marker[7]. In models of metabolic liver disease, galectin-3 ablation can separate steatosis from the accompanying inflammation and fibrosis, which is consistent with an amplifying role in fibroinflammatory progression rather than a simple reflection of lipid burden[8]. Consistent with that view, liver-biopsy analyses from patients with steatotic liver disease show marked macrophage heterogeneity but overall higher galectin-3 expression in more advanced disease, supporting continued interest in LGALS3 as a druggable macrophage-associated target[12].

In this study, LGALS3 is placed within a macrophage program that connects inflammatory activation with ferroptosis susceptibility. In vitro, inflammatory stimulation increases LGALS3; LGALS3 gain-of-function amplifies inflammatory outputs and coincides with GPX4 suppression and higher iron/lipid peroxidation indices, whereas LGALS3 knockdown shifts these readouts in the opposite direction[5]. Taken together, these findings fit current thinking that macrophage activation can reshape redox programs and iron handling and thereby influence whether injury remains signaling-dominant or progresses toward overt cellular damage[2,14].

How TRAF6 connects immune wiring to GPX4-dependent ferroptosis defense

TRAF6 is proposed as the link between LGALS3 and GPX4. That interpretation is biologically credible because TRAF6 is a well-established signal transducer and E3 ubiquitin ligase in toll-like receptor/interleukin-1 receptor signaling, where it can contribute to NLRP3 inflammasome priming[10]. In the featured study, pharmacologic TRAF6 inhibition partly reversed the LGALS3-associated changes in iron loading and GPX4-related readouts, giving the pathway stronger directional support than a purely correlative omics finding[5].

This leads to a more specific mechanistic question: Can TRAF6 alter GPX4 stability or activity in a biologically credible way? Evidence from nonhepatic systems suggests that such an effect is feasible. TRAF6 has been shown to ubiquitinate GPX4 and promote its p62-linked selective autophagic degradation, offering a concrete biochemical route through which TRAF6 could weaken GPX4-dependent resistance to ferroptosis[15]. Although these data were not generated in liver tissue or macrophages, they still support the biochemical feasibility of a model in which an innate immune adaptor/E3 Ligase directly modulates the principal brake on ferroptosis.

Ferroptosis as a tractable injury layer in steatohepatitis

Ferroptosis integrates oxidative stress, iron dysregulation, and inflammatory injury[3,13]. Recent overviews of metabolic dysfunction-associated steatotic liver disease (MASLD)/MASH further indicate that its contribution is not uniform across hepatic compartments, but shifts with the cell population involved and the stage of disease[13,14]. In steatohepatitis models, inhibiting ferroptosis can attenuate early necrotic injury and subsequent immune infiltration, supporting the view that ferroptotic susceptibility may precede inflammatory escalation instead of merely emerging as a late by-product[16]. This is relevant to the proposed LGALS3-TRAF6-GPX4 axis: If macrophage programs weaken GPX4 defenses, the tissue may become more permissive to ferroptosis, with downstream amplification of inflammation through damage-associated signals.

What remains to be proven

The axis is biologically plausible, but several questions remain open. First, current whole-liver readouts and RAW264.7 data do not establish that macrophage ferroptosis is necessary for the antifibrotic effect, nor do they demonstrate that macrophage LGALS3 is the dominant upstream determinant in vivo[5]. Recent evidence indicates that macrophage NCF1 drives Kupffer-cell iron overload and ferroptosis in MASH, supporting a role for cell-restricted ferroptotic programs in disease progression[11]. The same finding also suggests that the dominant pathogenic compartment may differ between models. A second unresolved issue is context: The consequences of ferroptosis may differ among cell populations and across stages of disease[13,14]. From a translational perspective, it therefore matters whether the decisive event lies in hepatocytes, macrophages, or redox remodeling adjacent to ferroptosis. If TRAF6 indeed links inflammatory signaling to GPX4 degradation in hepatic macrophages, cell-specific genetic validation would shift this model closer to causal inference. Figure 1 outlines the proposed LGALS3-TRAF6-GPX4 macrophage axis and the translational readouts that could be used to interrogate it.

Figure 1 Proposed macrophage-centered LGALS3-TRAF6-GPX4 axis and translation-ready development priorities in metabolic dysfunction-associated steatohepatitis. The left panel maps out the biological events connecting choline-deficient, L-amino acid-defined, high-fat diet-induced steatohepatitis to macrophage activation. In this setting, Kupffer cells increase cytokine release and drive up LGALS3 expression. LGALS3 then pushes TRAF6/NLRP3 inflammatory signals forward while simultaneously shutting down GPX4 ferroptosis defenses. This dual disruption leaves the liver highly vulnerable to iron accumulation and lipid peroxidation, fueling continuous tissue damage. Qiweizhigan (QWZG) apparently intervenes across several of these pathological nodes. The formula calms overall macrophage activity, cuts off the LGALS3/TRAF6 signal, and restores GPX4 protective functions. The right panel shifts focus to the practical steps required for clinical translation. Developers must establish potency tests based on this exact mechanism and enforce strict quality-control rules to ensure batch consistency. The final phase involves determining the right clinical fit. Researchers will need target-engagement biomarkers and noninvasive risk scores to figure out if the therapy works best as an add-on, sequential, or combination treatment. Solid arrows track the underlying biological chain of events. Blue dashed lines pinpoint exactly where QWZG disrupts the cascade. CDAHFD: Choline-deficient, L-amino acid-defined high-fat diet; MASH: Metabolic dysfunction-associated steatohepatitis; NIT: Noninvasive test; QWZG: Qiweizhigan granule.

REFRAMING “MULTI-COMPONENT” AS AN ADVANTAGE; IF TRANSLATION IS ENGINEERED

In the featured model, the LGALS3-TRAF6 inflammatory program lies upstream of impaired GPX4-centered ferroptosis defense. This arrangement points to measurable nodes that can be perturbed and then used in potency assessment. Even so, network logic alone will not be enough to support broad international acceptance of a multi-herb formula. To use this formula in the clinic, makers must be able to produce it exactly the same way every time. The manufacturing process needs tight control. Each batch must match the others, and the biological tests must stay accurate even when production scales up or moves to different labs[17-20]. These references are cited here not as disease-specific MASH studies, but because they define the methodological standards-raw-material authentication, contaminant control, and chemical consistency-that any multicomponent botanical therapy must satisfy before disease-oriented translation can be judged credibly[19,20].

From network narratives to measurable, mechanism-linked potency

For complex botanical formulations, enforcing pharmaceutical-grade manufacturing controls remains the primary hurdle. Regulatory frameworks dictate that such mixtures progress only when their chemistry, manufacturing, and control (CMC) specifications accurately reflect clinical safety and behavior[17-20]. Investigators do not need to purify a single active compound. Instead, they must prove that every manufactured batch maintains the same chemical signature and predictably triggers the intended biological response.

Evaluating drug potency through its underlying mechanism effectively bridges early preclinical findings with subsequent human trials. For the proposed macrophage axis, assay development could start with standard cell lines before advancing to primary human macrophages. Laboratory readouts must capture LGALS3/TRAF6 engagement and concurrently validate GPX4-dependent ferroptosis protection. Such a strategy avoids attempting to duplicate the complete MASH pathology ex vivo. Rather, the field primarily requires a robust screening tool sensitive enough to catch lot-to-lot manufacturing variations. Regulatory authorities endorse this evaluation framework because it delivers tangible proof of pharmacological stability, moving past simple historical claims of traditional use[18,19] (Figure 1).

Quality control, lot comparability, and constituent prioritization

After establishing potency, investigators are expected to examine chemical and biological equivalence together[19,20]. In the analysis of traditional Chinese medicines, investigators typically rely on chromatographic fingerprinting and multi-marker profiling just to quantify these intricate plant mixtures[20,21]. This level of analytical depth is strictly required whenever clinical success relies upon the crosstalk between phytochemicals. Global health authorities require these profiles to correspond directly with identity, purity, and bioactivity standards. That is the only reliable way to prevent batch-to-batch functional drift[19,20].

The “quality marker” (Q-marker) strategy offers a direct solution here. Scientists apply this concept to disregard everything but the specific ingredients governing safety, efficacy, or production traits. Doing so anchors quality control in actual biological function rather than arbitrary chemical selection[22]. Q-marker frameworks merge process controls with safety indicators, translating massive chemical datasets into definitive batch-release rules[22]. The recent botanical literature contains ample guidelines for systematically validating these marker panels[23]. Moving past conventional techniques, processing multimodal analytical datasets through artificial intelligence yields high accuracy in detecting flawed herbal batches. This shift shows that quality assessment has moved beyond isolated chemical platforms[24]. For the specific macrophage-ferroptosis pathway, an ideal screening panel would target the exact compounds dampening LGALS3/TRAF6. The panel needs to additionally monitor whichever elements safely control cellular iron and redox states.

Ultimately, bringing a multi-herb formula to the clinic means turning its complex chemistry into plain manufacturing rules. Using this approach, potency tests check the basic activity, while fingerprints and Q-markers prove the batches are similar. Strict CMC rules then maintain stability during large-scale production. Without such strict planning, making general statements about hitting multiple targets will not hold up well in current MASH research, which pays close attention to specific mechanisms.

CLINICAL TRANSLATION PRIORITIES IN THE CURRENT MASH LANDSCAPE

To actually use this idea in the clinic, a strong biological theory is not enough. Future studies and ways of picking patients have to compare the LGALS3-TRAF6-GPX4 pathway against current MASH treatments[25,26]. Now that resmetirom is approved, the medical community is no longer just looking at whether a single drug works on its own. Instead, they want to figure out how to use new treatments in everyday practice, which order to prescribe them in, and the best ways to mix them[25,27,28].

Target engagement biomarkers that fit real-world workflows

For these new markers to work in real clinics, doctors need to be able to add them to the MASH tests they already use. Right now, doctors usually start with routine blood draws such as fibrosis-4. After that, they confirm the results using scans such as elastography or other specific blood panels[29,30]. In research studies, tools that combine different test results, such as FAST, do a good job of finding patients who have both active liver inflammation and serious fibrosis. Using these tools helps trials run faster and gives doctors clearer information for treating patients[26,31]. The MAESTRO trial is a good example of this approach. It shows how to combine tissue biopsy results with blood tests, imaging scans, and long-term patient health tracking[27,28].

Testing a drug that targets macrophages or ferroptosis takes more than one type of test. Researchers need to start with standard non-invasive tests (NITs) and combine them with blood or tissue checks that measure LGALS3/TRAF6 activity and GPX4 oxidative stress. Over time, doctors can watch how the NIT scores change while also checking normal liver health markers[26,29-31]. Right now, these pathway tests are just for exploring how the drug works in the body. They are not ready to be used as strict rules for making clinical choices. Blood tests for MASH are getting much better, which means patients might avoid liver biopsies in some situations[32]. Even so, standard tests for fibrosis and metabolic stress are much further along in the clinic than these new macrophage and ferroptosis markers[33,34]. Using these new tests will not replace regular tissue biopsies. What they do is give early clinical trials a simple way to see if the drug hits its target and help figure out the best dose.

Patient segmentation beyond “one-size-fits-all”

Because MASH is biologically very complex, treatments that target the immune system or ferroptosis will likely work differently depending on the patient group[25,26,35,36]. Following current medical guidelines, doctors usually group patients by looking at two main things: Their existing metabolic problems (like obesity, type 2 diabetes, and high cholesterol) and how much active liver inflammation they have. Doctors typically measure this inflammation using NIT scores and blood markers[35,36]. Applying this idea to real clinics is easy. This suggests that individuals with significant inflammatory or iron-stress markers are prime candidates for interventions that restrict macrophage activation and maintain GPX4 defenses. On the other hand, patients whose main issue is severe metabolic disease will still need to focus heavily on losing weight or taking specific metabolic drugs as their main treatment. Recent expert reports agree with this approach. They predict that liver drugs like resmetirom and whole-body incretin drugs will be used together in daily practice from now on[37].

Positioning with existing therapies: Add-on, sequence, or combination

Contemporary hepatology practice is increasingly shifting toward combination therapies and sequential treatment strategies. Rather than relying on a single monotherapy, clinicians use distinct drug classes to address specific drivers of the disease. For example, certain medications are chosen to manage metabolic and lipid disturbances, while others are aimed at reducing immune activation or fibrotic progression[35-37]. In this setting, a macrophage- or ferroptosis-focused intervention would most plausibly be positioned as an add-on to approved metabolic therapy, including resmetirom, when residual inflammatory injury remains despite metabolic improvement. It could also be evaluated as a sequential option after partial response to resmetirom or related backbone therapy, or as a combination partner in patients with prominent inflammatory and oxidative-stress features at baseline. Previous trials with galectin-3 inhibitors highlight both the potential and the risks of this approach. For example, belapectin was safe for MASH cirrhosis patients with portal hypertension. However, the drug failed to meet its main goal for the whole group. It only showed a slight benefit for a smaller group of patients who did not have varices at the start of the study[38]. The lesson from these past studies is clear. To get a macrophage-centered therapy through clinical trials, researchers must pick the exact right patients, group them using strict biomarkers, and choose specific clinical goals to measure.

Safety, herb-drug interaction risk, and regulatory planning

From day one, any global clinical development plan for a botanical MASH intervention must anticipate heavy polypharmacy. Systematic reviews suggest that many herb-drug interactions are not severe, but clinically meaningful interactions do occur, often through cytochrome P450 pathways and transport systems. Interaction risk therefore requires direct testing and should not be judged from historical use alone[39]. Clinicians are also increasingly alert to herbal- and dietary-supplement-induced liver injury, which makes standardized manufacturing, contaminant control, and appropriate safety monitoring particularly important when botanical products are intended for patients with liver disease[40]. This concern becomes greater when a botanical intervention is considered alongside liver-directed or incretin-based backbone therapy in patients with multimorbidity and multiple medications.

Ultimately, satisfying regulatory requirements will depend on a few practical milestones. The manufacturing process needs a solid CMC framework to guarantee batch consistency. Additionally, because patients often take multiple drugs, the development plan must thoroughly address potential interactions with standard cardiometabolic medications. Chronic treatment will also require long-term safety data, with a specific focus on monitoring liver-related adverse events[39,40]. Table 1 details the primary steps and decisions needed to successfully bring this biological model into clinical practice.

Table 1 Translational deliverables for evaluating LGALS3-TRAF6-GPX4 axis in metabolic dysfunction-associated steatohepatitis.

Domain	Specimen/system	Assay/readout	Translational purpose	Decision impact
Disease staging and baseline risk	Serum/plasma; elastography platform	FIB-4; ELF where available; VCTE; FAST or other validated composite NITs	Define baseline disease severity and enrich for patients with active steatohepatitis and clinically meaningful fibrosis	Trial enrichment; subgroup definition; baseline comparability
Exploratory target engagement	Liver tissue; serum/plasma; macrophage assay systems	Liver LGALS3/TRAF6/GPX4 by immunohistochemistry or immunoblotting; circulating LGALS3; oxidative/iron-stress readouts such as lipid peroxidation and iron-related indices	Determine whether the proposed axis is modulated in vivo or ex vivo after intervention	Proof-of-mechanism; early pharmacodynamic assessment
Potency definition	Standardized macrophage-based bioassay	LGALS3/TRAF6 pathway activity under defined stimulation; GPX4-related redox and iron-handling readouts; predefined acceptance range for active batches	Define what constitutes an active and comparable batch of the final formulation	Batch release; comparability across production lots and study sites
Chemistry and quality control	Raw materials and finished product	Botanical authentication; chromatographic fingerprinting; prioritized marker/Q-marker panel; contaminant and stability testing	Link chemical consistency to biological consistency and manufacturing control	Regulatory readiness; manufacturing scalability; batch-to-batch reproducibility
Human relevance and model bridging	Primary human Kupffer cells; precision-cut liver slices; metabolically relevant animal models	Directional validation of axis modulation across human-relevant systems and obesity-linked disease models	Reduce the risk that the mechanism is restricted to a single mouse model or immortalized macrophage line	External validity; confidence for clinical translation
Clinical positioning and safety	Clinical development plan; medication-exposure context	Predefined add-on/sequence/combination hypothesis; herb-drug interaction assessment; liver-specific safety monitoring	Clarify where the intervention could fit in the current MASH treatment landscape and whether chronic use is feasible	Clinical adoption pathway; risk mitigation; go/no-go decisions
Durability and fibrosis-linked benefit	Longitudinal animal studies and, later, clinical follow-up datasets	Repeated histology where appropriate; fibrosis-related NIT trajectories; relapse/stressor robustness	Distinguish transient biochemical improvement from sustained fibrosis-relevant benefit	Phase-transition value; long-term development relevance

ELF: Enhanced liver fibrosis test; FAST: FibroScan-aspartate aminotransferase score; FIB-4: Fibrosis-4; NIT: Noninvasive test; MASH: Metabolic dysfunction-associated steatohepatitis; Q-marker: Quality marker; VCTE: Vibration-controlled transient elastography.

EXPERIMENTAL PRIORITIES TO ESTABLISH CAUSALITY AND TRANSLATABILITY

The proposed LGALS3-TRAF6-GPX4 chain is attractive because it links macrophage inflammatory amplification with ferroptotic susceptibility in a compact way. The main risk is that the pathway may prove model-dependent, cell-type-ambiguous, or merely correlative rather than necessary. A useful experimental roadmap should therefore test generalizability across disease contexts, localize causality to specific hepatic compartments, and align preclinical readouts with the biomarker and therapeutic positioning required for development. Figure 2 summarizes the proposed roadmap for causal and translational validation of the LGALS3-TRAF6-GPX4 axis.

Figure 2 Experimental roadmap for establishing causality and translatability of the macrophage-centered LGALS3-TRAF6-GPX4 axis in metabolic dysfunction-associated steatohepatitis. The figure details a follow-up experimental strategy for investigating the macrophage-driven LGALS3-TRAF6-GPX4 axis, moving past basic efficacy observations. The plan highlights several core steps. Investigators must first confirm these effects in highly metabolic animal models and run cell-specific causality tests within hepatic myeloid populations. It is also critical to reproduce the pathway responses in human-derived setups, such as primary Kupffer cells or precision-cut liver slices. Additional steps involve using chemical inhibitors to verify the exact ferroptosis link, followed by long-term tracking to ensure the fibrosis reduction holds up over time. Completing this sequence provides the biological certainty required to advance the therapy and define its clinical role in metabolic dysfunction-associated steatohepatitis. CDAHFD: Choline-deficient, L-amino acid-defined high-fat diet; NIT: Noninvasive test.

Multi-model validation with metabolically relevant contexts

CDAHFD efficiently induces steatohepatitis and fibrosis, but it does not reproduce the obesity and insulin-resistance context that dominates human MASH[41,42]. To reduce mechanistic uncertainty, both efficacy and axis engagement should be reproduced in at least one obesity-linked model, such as a Western diet or a high-fat/high-fructose regimen, while CDAHFD is retained as a mechanistic comparator[43,44]. Comparative studies show that CDAHFD and classic choline- or methionine-deficient diets do not produce the same lipidomic or pathophysiological profile. Diet composition can therefore materially affect the extent to which a model resembles human disease[41,43]. Older deficiency models can also induce steatohepatitis in the absence of insulin resistance, which limits their value when a single dietary model is used as the main translational reference[42]. If greater metabolic relevance is needed, additional comparators may be more informative. These include streptozotocin plus a high-fat diet, translational MASLD models with severe obesity, and models with a human-like bile acid profile, because such systems incorporate obesity, diabetes, or progressive fibroinflammatory features more clearly than classic deficiency models[44-46]. Demonstrating that QWZG modulates the LGALS3-TRAF6-GPX4 axis and improves injury/fibrosis in one of these settings would strengthen external validity.

Cell-type anchoring in human-relevant systems

Claims centered on Kupffer cells will be much stronger if they move beyond immortalized macrophage lines. A staged plan would begin with primary murine Kupffer or monocyte-derived macrophages and then, where possible, extend to primary human Kupffer cells, as methods for isolating and culturing these cells from normal human liver are already available[47,48]. In parallel, precision-cut liver slices (PCLS) provide an ex vivo system that preserves multicellular architecture and allows pathway responses to be examined after defined perturbations. PCLS have already been used to assess antifibrotic interventions with readouts consistent with in vivo findings, and the same platform can be extended to macrophage-driven mechanisms[47,49,50]. They are also useful for early method development because slice-based systems have been applied in toxicologic and translational settings, whereas reductionist human liver cell models differ widely in cell source, maturity, and functional stability[51,52]. Both systems also reveal donor-to-donor variability, which is relevant to biomarker-led development.

Genetics-based causality and “necessity” testing in vivo

Proving that this mechanism actually works in living models is the next required step. Researchers could test this by blocking the pathway only in hepatic myeloid cells. For example, they could use a conditional knockout or silence LGALS3/TRAF6 in Kupffer cells and monocyte-derived macrophages. This setup would show if QWZG can still improve tissue and molecular readouts when the targets are missing[53,54]. Past studies on MASH highlight the need to look at specific cells. As an example, ATG16 L1 in macrophages controls the disease through lipophagy. On the other hand, removing MST1/2 worsens inflammation and fibrosis by turning on YAP. Also, myeloid grancalcin and defective TIM4 efferocytosis both clearly push fibrosis forward[55,56].

In addition to knocking out genes, rescue experiments are another practical option. If QWZG works mainly by lowering LGALS3/TRAF6 signals and protecting GPX4, forcing these pathways to stay active should reduce the drug’s benefits. Researchers could do this by keeping LGALS3 or TRAF6 active, or by removing GPX4 from these myeloid populations. Tests like this help answer a basic question. They show if the treatment simply stops the inflammasome directly, or if it stops communication between macrophages and other local cells, like liver sinusoidal endothelial cells[6,57].

Pharmacologic “challenge probes” to triangulate ferroptosis involvement

Researchers can test the ferroptosis component with standard drugs before moving on to complex genetic models. If the treatment works by changing ferroptotic susceptibility, then known ferroptosis inhibitors should produce similar effects. Specifically, they should recreate some of the benefits seen in oxidative stress, iron levels, and tissue injury. After that, additivity tests can help show whether the effect is specific to ferroptosis or just a general decrease in immune and metabolic activity[58,59]. Prior studies using liproxstatin-1 and ferrostatin-1 in fatty liver models provide a helpful reference point for this[58,59]. In the end, the results need to agree with each other. If ferroptosis really drives this pathway, different ways of blocking it should lead to similar findings.

Durability, fibrosis regression, and clinically aligned endpoints

Claims about mechanisms are much stronger when the benefits last over time and actually reduce fibrosis[60]. Researchers can check this by taking samples at multiple time points. Using tissue biopsies along with noninvasive tests helps show if the drug’s effect is temporary or if it lasts long enough to change tissue remodeling[60,61]. It also helps to add real-world challenges to the experiments. For example, changing the diet, allowing metabolic relapse, or adding extra inflammation makes the test more realistic. These extra steps help prove if the drug targets the real disease or if it only works in a specific lab setup. This level of testing is required because the field evaluates new preclinical drugs using the exact same rules doctors use to track MASLD in patients right now[61]. Finally, Table 2 lists what we currently know, what questions remain, and what studies should be done next to move this toward the clinic.

Table 2 Evidence status and next-step validation of the proposed LGALS3-TRAF6-GPX4 framework.

Domain/claim	Current support	Key gap	Priority next step	Translational impact
QWZG efficacy in experimental MASH	Improved histology, fibrosis-associated readouts, and oxidative/iron-stress indices in CDAHFD	Generalizability to obesity-linked disease settings is unknown	Validate efficacy and axis modulation in at least one obesity-associated model	External validity
LGALS3 as an upstream node	Macrophage-associated amplifier supported by the featured study and prior liver disease literature	Driver vs correlated marker remains unresolved in vivo	Myeloid/Kupffer cell-focused LGALS3 perturbation with rescue design	Target nomination
TRAF6-GPX4 linkage	TRAF6 inhibition supports directionality; external studies provide biochemical precedent	Direct regulation in hepatic macrophages is unproven	Cell-specific Traf6 manipulation plus GPX4 rescue or depletion	Mechanistic confidence
Macrophage ferroptosis as a disease layer	Ferroptosis is supported as an injury amplifier; Kupffer cell ferroptosis has experimental support	Dominant pathogenic cell compartment remains uncertain	Compare hepatocyte and macrophage ferroptosis readouts across models and time points	Actionable cell context
Kupffer cell necessity	Macrophage-line and whole-liver data are consistent with involvement	In vivo necessity is not established	Primary Kupffer cell validation and myeloid-compartment necessity testing	From plausibility to causality
Human relevance	The framework is biologically coherent and testable in human-oriented systems	Primary human Kupffer cell or PCLS confirmation is lacking	Validate in primary human Kupffer cells and/or precision-cut liver slices	Translational confidence
Formula-to-axis specificity	Pathway association is shown after QWZG exposure	Active constituents, direct targets, and composition-function linkage remain undefined	Potency-linked constituent prioritization and Q-marker construction	CMC readiness
Clinical development readiness	The axis offers an exploratory pharmacodynamic framework	No validated thresholds, positioning strategy, or interaction package	Develop exploratory biomarker assays plus add-on/sequence and safety plans	Clinical positioning

CDAHFD: Choline-deficient, L-amino acid-defined high-fat diet; CMC: Chemistry, manufacturing, and controls; MASH: Metabolic dysfunction-associated steatohepatitis; PCLS: Precision-cut liver slices; Q-marker: Quality marker.

CONCLUSION

The present data indicate that QWZG reduces experimental MASH severity, likely via the LGALS3-TRAF6-GPX4 cascade in macrophages. At this point, however, researchers cannot definitively state that this specific signaling route is strictly required in living subjects. It also remains unclear whether identical mechanisms operate across different metabolic environments or in human patients. Consequently, this investigation establishes a foundation for new hypotheses, not an immediate clinical guideline. Subsequent research must replicate these anti-fibrotic outcomes in varied disease settings and confirm their long-term durability.

ACKNOWLEDGEMENTS

We would like to thank all the professionals who contributed to the discussion and elaboration of this review.